CMTTdb

An integrated database for cancer molecular targeted thearpies

Entry Detail


General information
Database:DB00743
Objective: Epidermal growth factor receptor tyrosine kinase inhibitors are effective as firstline therapy for advanced non small cell lung cancer patients harboring epidermal growth factor receptor mutations. however, it is unknown whether secondline platinumbased chemotherapy after epidermal growth factor receptor tyrosine kinase inhibitor therapy could lead to better outcomes. they evaluated the efficacy of secondline platinumbased chemotherapy after gefitinib for advanced non small cell lung cancers harboring epidermal growth factor receptor mutations (the NEJ002 study).
Authors:Miyauchi E, et al
Title:Efficacy of chemotherapy after firstline gefitinib therapy in EGFR mutationpositive advanced non small cell lung cancerdata from a randomizedphase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
Journal:Jpn J Clin Oncol.
Year:2015
PMID:25877748
Trial Design
Clinical Trial Id:NA
Agent:gefitinib
Target:Epidermal growth factor receptor
Cancer Type:non small cell lung cancer
Cancer Subtype:advanced non small cell lung cancer harboring epidermal growth factor receptor mutations
Therapy Type:com
Therapeutic Combination Type:2
Therapeutic Combination Content:chemotherapy after firstline gefitinib therapy
Study Type:posthoc analysis of a multicenter, randomized, phase III trial (The NEJ00II study )
Key Patients Feature:Eligibility criteria for NEJ002 included the presence of advanced non small cell lung cancer harboring activating EGFR mutations (excluding the resistant EGFR mutation T790M examined by the PNALNA polymerase chain reaction clamp method), no history of chemotherapy, age less than and equal to 75 years, performance status 0-1, appropriate organ functions and written informed consent.
Biomarker: EGFR mutationpositive
Biomark Analysis: In the analysis of epidermal growth factor receptor mutation types, the objective responses of deletions in exon 19 and a point mutation in exon 21 (L858R) were 27.3% (9/33) and 28.1% (9/32), respectively, but these differences between objective response rates were not significant.
Control Group Info:gefitinib as firstline therapy and then receiving platinumbased chemotherapy as secondline therapy
Treatment Info:patients were evaluated for antitumor response to secondline chemotherapy by computed tomography according to the criteria of the Response Evaluation Criteria in Solid Tumors group (version 1.0).
Primary End Point:efficacy
Secondary End Point:NA
Patients Number:71
Trial Results
DLT_MTD:NA
Objective Response Rate:25.40%
Disease Control Rate:69%
Median Time to Progression:NA
Median PFS A vs. C:NA
Median OS A vs. C:The median survival time of patients receiving platinumbased chemotherapy after firstline gefitinib was 28.9 months.
Adverse Event(agent arm):NA
Conclusions:The efficacy of secondline platinumbased chemotherapy followed at progression by gefitinib was similar to firstline platinumbased chemotherapy, and epidermal growth factor receptor mutation types did not influence the efficacy of secondline platinumbased chemotherapy.